Novel anti-inflammatory and analgesic agents: synthesis, molecular docking and <i>in vivo</i> studies
作者:David Izuchukwu Ugwu、Uchechukwu Christopher Okoro、Pius Onyeoziri Ukoha、Astha Gupta、Sunday N. Okafor
DOI:10.1080/14756366.2018.1426573
日期:2018.1.1
in vivo anti-inflammatory, analgesic and ulcerogenic activities. Molecular docking showed an excellent binding interaction of the synthesised compounds with the receptors, with 17c showing the highest binding energy (-12.50 kcal/mol). Compounds 17c and 17i inhibited carrageenan-induced rat paw oedema at 72, 76, and 80% and 64, 73, and 78% at 1 h, 2 h, and 3 h, respectively. In the analgesic activity
合成了十二种带有苯并噻唑的苯磺酰胺和羧酰胺的新衍生物,并研究了它们的体内抗炎,镇痛和促溃疡活性。分子对接显示出合成化合物与受体的极佳结合相互作用,其中17c显示出最高的结合能(-12.50 kcal / mol)。化合物17c和17i分别在1 h,2 h和3 h抑制角叉菜胶诱导的大鼠爪水肿,分别为72%,76%和80%,64%,73%和78%。在镇痛活性实验中,化合物17c,17 g和17i在0.5小时后的ED50(µM / kg)为96、127和84。1小时后分别为102、134和72,2小时后分别为89、156和69 µM / kg,这与塞来昔布的156、72和70 µM / kg相当。活性最高的衍生物17c和17i的致溃疡指数分别为0.82和0.89,分别相当于塞来昔布的0.92。新衍生物的理化研究表明,它们不会出现口服生物利用度问题。